Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases [Yahoo! Finance]
Mustang Bio, Inc. (MBIO)
Last mustang bio, inc. earnings: 11/12 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
mustangbio.com/investor-relations
Company Research
Source: Yahoo! Finance
MB-106 data in B-cell non-Hodgkin lymphoma (NHL) provide a strong foundation for future development in autoimmune disease; pivotal trial for Waldenstrom macroglobulinemia (WM) is expected to initiate in the second half of 2024 WORCESTER, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy. MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”). Mustang and Fred Hutch are in preliminary discussions to explore a potential Phase 1 investigator-sponsored clinical trial to evaluate MB-106 for the treatment of autoimmune diseases. “Mustang is leveraging its
Show less
Read more
Impact Snapshot
Event Time:
MBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBIO alerts
High impacting Mustang Bio, Inc. news events
Weekly update
A roundup of the hottest topics
MBIO
News
- Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesGlobeNewswire
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade Glioma [Yahoo! Finance]Yahoo! Finance
- Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Ra2-targeted CAR T-Cells in High-Grade GliomaGlobeNewswire
MBIO
Earnings
- 11/14/23 - Beat
MBIO
Sec Filings
- 4/12/24 - Form 8-K
- 4/2/24 - Form S-1/A
- 3/29/24 - Form 8-K
- MBIO's page on the SEC website